Sacituzumab tirumotecan reduces progression and death in recurrent endometrial cancer
Published on 26 October 2026
Dr Bhavana Pothuri speaks to ecancer about a landmark phase III study, TroFuse-005/ENGOT-en23/GOG-3095.
The study demonstrated that sacituzumab tirumotecan (sac-TMT) improves outcomes in patients with advanced or recurrent endometrial cancer previously treated with chemotherapy and immunotherapy.
Compared with standard chemotherapy, sac-TMT reduced the risk of disease progression or death by 41% and the risk of death by 32%.
Dr Pothuri says that objective response rates were also higher with sac-TMT (35.1% versus 17.3%).
The findings highlight the potential of this Trop-2-directed antibody drug conjugate to expand treatment options for patients with recurrent disease.
This information is intended for health care professionals only. The information is not intended for US health care professionals.